Eli Lilly and Company $LLY Shares Sold by Verity Asset Management Inc.

Verity Asset Management Inc. decreased its position in Eli Lilly and Company (NYSE:LLY) by 56.1% during the 4th quarter, Holdings Channel reports. The firm owned 561 shares of the company’s stock after selling 717 shares during the quarter. Verity Asset Management Inc.’s holdings in Eli Lilly and Company were worth $603,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of LLY. Capital Research Global Investors grew its holdings in Eli Lilly and Company by 20.9% in the third quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock valued at $19,141,787,000 after purchasing an additional 4,332,008 shares during the last quarter. Vanguard Group Inc. grew its holdings in Eli Lilly and Company by 1.2% in the fourth quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock valued at $88,087,193,000 after purchasing an additional 1,006,885 shares during the last quarter. Amundi grew its holdings in Eli Lilly and Company by 27.1% in the third quarter. Amundi now owns 4,525,902 shares of the company’s stock valued at $3,823,977,000 after purchasing an additional 964,675 shares during the last quarter. Jennison Associates LLC grew its holdings in Eli Lilly and Company by 22.3% in the fourth quarter. Jennison Associates LLC now owns 5,133,676 shares of the company’s stock valued at $5,517,059,000 after purchasing an additional 937,204 shares during the last quarter. Finally, Victory Capital Management Inc. grew its holdings in Eli Lilly and Company by 47.6% in the third quarter. Victory Capital Management Inc. now owns 2,309,006 shares of the company’s stock valued at $1,761,772,000 after purchasing an additional 744,868 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q1 beat and raised outlook — Lilly reported revenue of $19.8B (+55.5% YoY) and non?GAAP EPS of $8.55, topping estimates and lifting the company’s FY guidance, which supports stronger near?term earnings growth. Results: Eli Lilly and Company Beat Earnings Expectations And Analysts Now Have New Forecasts
• Positive Sentiment: Blockbuster GLP?1 sales and new oral pill expand market opportunity — multiple reports note Lilly’s metabolic/weight?management drugs are delivering blockbuster revenue and that a new oral weight?loss therapy broadens addressable market, underpinning upside potential. Eli Lilly Just Announced Fantastic News for Shareholders
• Positive Sentiment: Wall Street and media support — analysts (Truist, BofA) reaffirm buy/see upside after trial/data and earnings, and high?profile coverage (e.g., Jim Cramer) is attracting fresh attention and flows into the name. Truist Reaffirms Buy on Eli Lilly (LLY) After Trial Success
• Neutral Sentiment: Sector?level caution on GLP?1 concentration — a Deloitte analysis flagged that GLP?1s have shifted late?stage pipeline value and could create a “bubble effect” in pharma, a macro/valuation risk to monitor even as Lilly benefits. ‘Bubble effect’: Weight loss drug fueled growth is putting the pharma sector at risk, report finds
• Neutral Sentiment: Supplemental investor materials — Lilly’s Q1 earnings presentation and analyst deep dives provide details on obesity?franchise expansion and pipeline investment; useful for modeling but not immediate market movers. Eli Lilly and Company 2026 Q1 – Results – Earnings Call Presentation
• Neutral Sentiment: Unrelated biotech financing — a large offering by Cabaletta Bio is market news for biotech capital markets but does not directly affect Lilly’s fundamentals. Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering
• Negative Sentiment: Price?target trim by BofA — Bank of America lowered its LLY price target from $1,294 to $1,133 while keeping a Buy rating, a reminder some upside may already be priced in and that valuation sensitivity exists. BofA Securities cuts Eli Lilly price target to $1,133 from $1,294; maintains Buy rating

Analysts Set New Price Targets

LLY has been the topic of several research reports. TD Cowen upped their target price on Eli Lilly and Company from $960.00 to $1,250.00 and gave the company a “buy” rating in a report on Thursday, January 29th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research note on Tuesday, March 10th. Royal Bank Of Canada initiated coverage on Eli Lilly and Company in a research note on Tuesday, February 24th. They set an “outperform” rating and a $1,250.00 price objective on the stock. UBS Group reaffirmed a “buy” rating on shares of Eli Lilly and Company in a research note on Wednesday, March 18th. Finally, Barclays assumed coverage on Eli Lilly and Company in a research note on Thursday, February 19th. They set an “overweight” rating and a $1,350.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $1,212.96.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $965.19 on Monday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The company has a market capitalization of $911.93 billion, a price-to-earnings ratio of 34.29, a PEG ratio of 1.13 and a beta of 0.48. The company’s 50 day simple moving average is $947.05 and its 200 day simple moving average is $987.36. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion for the quarter, compared to the consensus estimate of $17.82 billion. During the same quarter in the prior year, the firm posted $3.34 earnings per share. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 33.79 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.